[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=072e92f3a1e997a0bfd876287550531e34daec0db328f5bc07002a961e6a00d2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759422600,
      "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "id": 137018306,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=072e92f3a1e997a0bfd876287550531e34daec0db328f5bc07002a961e6a00d2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Is Up 7.4% After FDA Fast Track Win for Alzheimer’s Drug Candidate",
    "summary": "Bristol-Myers Squibb announced that its investigational anti-tau antibody BMS-986446, aimed at early Alzheimer's disease, received Fast Track Designation from the FDA, a regulatory milestone intended to expedite the drug's development and review process. This designation not only highlights the unmet need in Alzheimer's treatment but also underscores the potential of BMS-986446 to advance disease-modifying therapies in neurodegenerative medicine. We'll explore how this regulatory advancement...",
    "url": "https://finnhub.io/api/news?id=9d7556138a276d26cf1b79db98b2568b929d7adbe64042f1624f2b509df6913d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759421214,
      "headline": "Bristol-Myers Squibb (BMY) Is Up 7.4% After FDA Fast Track Win for Alzheimer’s Drug Candidate",
      "id": 136960312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb announced that its investigational anti-tau antibody BMS-986446, aimed at early Alzheimer's disease, received Fast Track Designation from the FDA, a regulatory milestone intended to expedite the drug's development and review process. This designation not only highlights the unmet need in Alzheimer's treatment but also underscores the potential of BMS-986446 to advance disease-modifying therapies in neurodegenerative medicine. We'll explore how this regulatory advancement...",
      "url": "https://finnhub.io/api/news?id=9d7556138a276d26cf1b79db98b2568b929d7adbe64042f1624f2b509df6913d"
    }
  },
  {
    "ts": null,
    "headline": "Can Novo Nordisk's Restructuring Program Drive its Return to Growth?",
    "summary": "NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.",
    "url": "https://finnhub.io/api/news?id=5ecdbb6bb9aa76efe900e8bfd0ab66674ce9010ba35dd8cfa6d4230a8d35473b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759418100,
      "headline": "Can Novo Nordisk's Restructuring Program Drive its Return to Growth?",
      "id": 136960112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "NVO is cutting 9,000 jobs, targeting DKK 8 billion in savings, and shifting focus to obesity and diabetes R&D to regain growth momentum.",
      "url": "https://finnhub.io/api/news?id=5ecdbb6bb9aa76efe900e8bfd0ab66674ce9010ba35dd8cfa6d4230a8d35473b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Alzheimer's Drug Earns FDA Fast Track",
    "summary": "Early-stage therapy targets tau protein to slow progression",
    "url": "https://finnhub.io/api/news?id=667247efd8088b983c6d0d2a05b6af49951652981e55b5bb0cedb793512b316b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759413214,
      "headline": "Bristol Myers Alzheimer's Drug Earns FDA Fast Track",
      "id": 136960314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Early-stage therapy targets tau protein to slow progression",
      "url": "https://finnhub.io/api/news?id=667247efd8088b983c6d0d2a05b6af49951652981e55b5bb0cedb793512b316b"
    }
  },
  {
    "ts": null,
    "headline": "Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?",
    "summary": "Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.",
    "url": "https://finnhub.io/api/news?id=44632e94c98f7b601cea2093b569b5c854eede02c53254a82c970404ea3835bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759410600,
      "headline": "Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?",
      "id": 136960315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.",
      "url": "https://finnhub.io/api/news?id=44632e94c98f7b601cea2093b569b5c854eede02c53254a82c970404ea3835bd"
    }
  },
  {
    "ts": null,
    "headline": "Chinese healthcare, biotech firms flock to Hong Kong for IPOs",
    "summary": "Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical - known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) - and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public offe",
    "url": "https://finnhub.io/api/news?id=7b5add546959ddfb4f60821b112e675e25bb4179be784d03186d37b9381ec0bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759397400,
      "headline": "Chinese healthcare, biotech firms flock to Hong Kong for IPOs",
      "id": 136955520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in the sector. The best-known names among them are online healthcare services firm We Doctor Holdings, Sichuan Biokin Pharmaceutical - known for a US$8.4 billion licensing deal with US-based Bristol Myers Squibb (BMS) - and profitable cancer-drug developer Betta Pharmaceuticals. Other initial public offe",
      "url": "https://finnhub.io/api/news?id=7b5add546959ddfb4f60821b112e675e25bb4179be784d03186d37b9381ec0bb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the top picks for a retirement portfolio. Bristol-Myers Squibb Company (NYSE:BMY) reported on September 23 that its Phase 3 EXCALIBER-RRMM trial using iberdomide combined with daratumumab and dexamethasone showed strong improvement in minimal residual disease negativity rates among individuals with relapsed or refractory multiple myeloma. Iberdomide belongs to a […]",
    "url": "https://finnhub.io/api/news?id=794f09323080c87d9e1c7918179b1a44f093471ddb1bfd2d57f300bc26dd609a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759386808,
      "headline": "Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data",
      "id": 136955521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the top picks for a retirement portfolio. Bristol-Myers Squibb Company (NYSE:BMY) reported on September 23 that its Phase 3 EXCALIBER-RRMM trial using iberdomide combined with daratumumab and dexamethasone showed strong improvement in minimal residual disease negativity rates among individuals with relapsed or refractory multiple myeloma. Iberdomide belongs to a […]",
      "url": "https://finnhub.io/api/news?id=794f09323080c87d9e1c7918179b1a44f093471ddb1bfd2d57f300bc26dd609a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers",
    "summary": "With significant upside potential, Bristol-Myers Squibb Company (NYSE:BMY) secures a spot on our list of the 20 NYSE Stocks with the Lowest P/E Ratios. Bristol-Myers Squibb Company (NYSE:BMY) announced on September 25, 2025, that it would begin selling its psoriasis medication Sotyktu directly to cash-paying U.S. customers at a price more than 80% lower than […]",
    "url": "https://finnhub.io/api/news?id=958d51a6bf2008023eebe2365d786dc3a5531bd4778bffe88527b46dae70c554",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759364405,
      "headline": "Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers",
      "id": 136952418,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "With significant upside potential, Bristol-Myers Squibb Company (NYSE:BMY) secures a spot on our list of the 20 NYSE Stocks with the Lowest P/E Ratios. Bristol-Myers Squibb Company (NYSE:BMY) announced on September 25, 2025, that it would begin selling its psoriasis medication Sotyktu directly to cash-paying U.S. customers at a price more than 80% lower than […]",
      "url": "https://finnhub.io/api/news?id=958d51a6bf2008023eebe2365d786dc3a5531bd4778bffe88527b46dae70c554"
    }
  }
]